ArticleCancer medicine2019

Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study.

Mette Søgaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.